MCID: ADN012
MIFTS: 45

Adenocarcinoma in Situ malady

Categories: Cancer diseases

Aliases & Classifications for Adenocarcinoma in Situ

Aliases & Descriptions for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4943
MeSH 42 D065311
NCIt 47 C4123
SNOMED-CT 64 51642000
UMLS 69 C0334276

Summaries for Adenocarcinoma in Situ

MalaCards based summary : Adenocarcinoma in Situ is related to large cell neuroendocrine carcinoma and fallopian tube adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Pathways in cancer and Mitotic G1-G1/S phases. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and testes, and related phenotypes are cellular and cardiovascular system

Related Diseases for Adenocarcinoma in Situ

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
id Related Disease Score Top Affiliating Genes
1 large cell neuroendocrine carcinoma 29.6 CDX2 KRAS KRT20
2 fallopian tube adenocarcinoma 29.2 CDKN1A CDKN2A CDX2 KRT20
3 in situ pulmonary adenocarcinoma 11.0
4 adenocarcinoma 10.7
5 cervicitis 10.4
6 cervical adenocarcinoma 10.3
7 endocervicitis 10.3
8 peritoneal benign neoplasm 10.3 CDX2 KRT20
9 dystonia 10.3 CDX2 KRT20
10 anal canal paget's disease 10.3 CDX2 KRT20
11 uterine ligament mucinous adenocarcinoma 10.3 CDX2 KRAS
12 agenesis and aplasia of uterine body 10.3 KRAS KRT20
13 clitoris cancer 10.3 CDX2 KRT20
14 ureter adenocarcinoma 10.2 CDX2 KRAS
15 kimura disease 10.2 PAX2 PAX8
16 extramedullary plasmacytoma 10.2 CDX2 KRT20
17 connective tissue disease 10.2 PAX2 PAX8
18 ovarian primitive germ cell tumor 10.2 PAX2 PAX8
19 testicular malignant germ cell cancer 10.2 CDKN2A WT1
20 gastrointestinal neuroendocrine tumor 10.2 PAX2 PAX8
21 cervix endometriosis 10.2 CDX2 KRT20
22 bladder adenocarcinoma 10.2 CDKN2A PAX2
23 breast ductal carcinoma 10.2 KRAS WT1
24 postpoliomyelitis syndrome 10.2 CDKN2A CDX2 KRAS
25 aicardi-goutieres syndrome 10.2 CDKN2A CDX2 KRAS
26 subareolar duct papillomatosis 10.2 CDKN2A PAX8
27 pelvic inflammatory disease 10.2 CDX2 KRAS KRT20
28 anemia of prematurity 10.2 CDX2 KRAS KRT20
29 superficial urinary bladder cancer 10.2 PAX2 PAX8
30 apocrine adenocarcinoma 10.2 CDX2 KRT20
31 giant cell tumor 10.2 CDX2 KRAS KRT20
32 mucinous adenofibroma 10.2 PAX2 WT1
33 papillary adenofibroma 10.2 CDX2 KRAS KRT20
34 sagittal sinus thrombosis 10.2 CDX2 KRAS KRT20
35 myotonia congenita 10.2 CDKN2A CDX2 KRT20
36 tabes dorsalis 10.2 CDX2 KRAS KRT20
37 neuroretinitis 10.2 CDX2 KRAS KRT20
38 mucosal melanoma 10.2 CDX2 KRT20
39 colon signet ring adenocarcinoma 10.2 KRT20 PAX2
40 pacinian tumor 10.2 CDKN2A CDX2 KRT20
41 exotropia 10.2 PAX8 WT1
42 oral squamous cell carcinoma 10.2 CDX2 KRAS KRT20
43 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.2 CDKN2A KRAS KRT20
44 neuroendocrine tumor 10.2 CDX2 KRT20
45 gastroesophageal junction adenocarcinoma 10.2 CDX2 KRAS KRT20
46 peripheral nervous system ganglioneuroblastoma 10.2 CDX2 WT1
47 paraphimosis 10.2 CDKN2A KRT20
48 avian influenza 10.2 CDKN2A WT1
49 benign shuddering attacks 10.2 CDKN2A KRAS PAX8
50 non-distal monosomy 10q 10.1 CDKN2A KRAS PAX8

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ

Symptoms & Phenotypes for Adenocarcinoma in Situ

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.01 CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
2 cardiovascular system MP:0005385 9.98 CDX2 KRAS PAX2 PAX8 WT1 CDKN1A
3 embryo MP:0005380 9.97 CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
4 endocrine/exocrine gland MP:0005379 9.92 WT1 CDKN1A CDKN2A CDX2 KRAS MCM2
5 mortality/aging MP:0010768 9.91 CDKN1A CDKN2A CDX2 CLDN1 KRAS MCM2
6 neoplasm MP:0002006 9.63 CDKN1A CDKN2A CDX2 KRAS MCM2 WT1
7 pigmentation MP:0001186 9.26 CDKN2A KRAS MCM2 PAX2
8 reproductive system MP:0005389 9.17 CDKN1A CDKN2A CDX2 KRAS PAX2 PAX8

Drugs & Therapeutics for Adenocarcinoma in Situ

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Cervarix 17 46 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009
2
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
2
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
3
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
4
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
6
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
8
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
9
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
10
Anastrozole Approved, Investigational Phase 3,Phase 1,Phase 2 120511-73-1 2187
11
Cetuximab Approved Phase 2, Phase 3,Phase 1 205923-56-4 56842117 2333
12
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
15
Metformin Approved Phase 3,Phase 2 657-24-9 14219 4091
16
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
17
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
18
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
19 Adjuvants, Immunologic Phase 3
20 Alkylating Agents Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2
22 Antibiotics, Antitubercular Phase 3,Phase 2
23 Anti-Infective Agents Phase 3,Phase 1,Phase 2
24 Antiviral Agents Phase 3,Phase 1,Phase 2
25 BCG Vaccine Phase 3
26 Interferon-alpha Phase 3
27 interferons Phase 3,Phase 1,Phase 2
28 Mitomycins Phase 3
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
30 Pharmaceutical Solutions Phase 3,Phase 2
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
33 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2
34 Estrogen Antagonists Phase 3,Phase 2,Phase 1
35 Estrogen Receptor Modulators Phase 3,Phase 2
36 Estrogens Phase 3,Phase 2,Phase 1
37 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
38 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
40 Selective Estrogen Receptor Modulators Phase 3,Phase 2
41 Antimetabolites Phase 3,Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
44 Angiogenesis Inhibitors Phase 2, Phase 3
45 Angiogenesis Modulating Agents Phase 2, Phase 3
46 Antidotes Phase 2, Phase 3,Phase 1
47 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
48 Calcium, Dietary Phase 2, Phase 3, Phase 1
49 Protective Agents Phase 2, Phase 3,Phase 1
50 Liver Extracts Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 179)
id Name Status NCT ID Phase
1 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
2 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
4 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Not yet recruiting NCT03180034 Phase 4
5 Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) Unknown status NCT01429649 Phase 3
6 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3
7 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
8 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
9 Efficiency of Two Dimensional High Definition Versus Three Dimensional Endoscopic Systems in Transanal Endoscopic Surgery Completed NCT01498354 Phase 3
10 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
11 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
12 Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery Completed NCT00647530 Phase 3
13 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
14 Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer Completed NCT00975897 Phase 2, Phase 3
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
16 Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer Recruiting NCT01905046 Phase 3
17 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3
18 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
19 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Active, not recruiting NCT00321048 Phase 3
20 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
21 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
22 Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
23 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2
24 C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Unknown status NCT02344810 Phase 1, Phase 2
25 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2
26 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
27 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2
28 Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Completed NCT00365716 Phase 2
29 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
30 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2
31 Phase II Study of Irinotecan and Panitumumab Completed NCT00836277 Phase 2
32 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
33 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2
34 Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Completed NCT00551421 Phase 1, Phase 2
35 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2
36 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Completed NCT00586326 Phase 2
37 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2
38 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor Completed NCT01372618 Phase 2
39 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
40 Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Completed NCT00655499 Phase 2
41 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2
42 Use of N-Acetylcysteine During Liver Procurement Completed NCT01394497 Phase 2
43 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2
44 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer Recruiting NCT03053544 Phase 2
45 Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer Recruiting NCT01931046 Phase 1, Phase 2
46 Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery Recruiting NCT02617082 Phase 2
47 Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery Recruiting NCT02694809 Phase 2
48 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2
49 Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) Recruiting NCT02730923 Phase 1, Phase 2
50 Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Recruiting NCT02636582 Phase 2

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Genetic Tests for Adenocarcinoma in Situ

Anatomical Context for Adenocarcinoma in Situ

MalaCards organs/tissues related to Adenocarcinoma in Situ:

39
Cervix, Lung, Testes, Lymph Node, Colon, Ovary, Appendix

Publications for Adenocarcinoma in Situ

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 253)
id Title Authors Year
1
Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies. ( 27565930 )
2016
2
Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. ( 27174927 )
2016
3
Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ. ( 27908632 )
2016
4
Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases. ( 27334141 )
2016
5
Syringocystadenocarcinoma Papilliferum In Situ, a Variant of Cutaneous Adenocarcinoma In Situ: A Case Report With Literature Review. ( 27533073 )
2016
6
Thin-section computed tomography-histopathologic comparisons of pulmonary focal interstitial fibrosis, atypical adenomatous hyperplasia, adenocarcinoma in situ, and minimally invasive adenocarcinoma with pure ground-glass opacity. ( 27666606 )
2016
7
Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung. ( 27597281 )
2016
8
Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma-analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. ( 27067781 )
2016
9
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. ( 27137345 )
2016
10
Case of anal adenocarcinoma in situ with pagetoid spread but without macroscopic abnormality in anal mucosa. ( 27666572 )
2016
11
Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. ( 27174588 )
2016
12
The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. ( 25956340 )
2015
13
Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. ( 25987897 )
2015
14
Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? ( 25769659 )
2015
15
Endocervical adenocarcinoma in situ presenting in fundal endometrial polyp: the mother of all skip lesions. ( 25844546 )
2015
16
Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. ( 25970685 )
2015
17
Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA). ( 26503035 )
2015
18
Conservative Treatment Seems the Best Choice in Adenocarcinoma In Situ of the Cervix Uteri. ( 25943864 )
2015
19
Cytological variations and typical diagnostic features of endocervical adenocarcinoma in situ: A retrospective study of 74 cases. ( 25972909 )
2015
20
Prognosis and status of lymph node involvement in patients with adenocarcinoma in situ and minimally invasive adenocarcinoma-a systematic literature review and pooled-data analysis. ( 26716039 )
2015
21
Coexistence of mature cystic teratoma and adenocarcinoma in situ within atypical proliferative mucinous tumour of ovary--a case report of 35-year-old woman. ( 26050362 )
2015
22
Cytological Diagnoses of Adenocarcinoma in situ of the Cervix: Common Misdiagnoses. ( 25766846 )
2015
23
Laparoscopic Oophorectomy and Radical Lymph Node Dissection for a Recurrent Adenocarcinoma In Situ of the Cervix. ( 27678792 )
2015
24
Extrafascial Hysterectomy Without Preoperative Conization is Unacceptable in Patients With Adenocarcinoma in Situ Diagnosed by Cervical Punch Biopsy or Endocervical Curettage. ( 27679125 )
2015
25
Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4A years after sublobar resection for adenocarcinoma in situ: report of a case. ( 25377270 )
2014
26
Papillary adenocarcinoma in situ of the skin: report of four cases. ( 24855569 )
2014
27
Can adenocarcinoma in situ of the uterine cervix be treated safely by conisation in combination with endocervical curettage? ( 25556275 )
2014
28
Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. ( 24472852 )
2014
29
Management of Adenocarcinoma In Situ of the Uterine Cervix: A Comparison of Loop Electrosurgical Excision Procedure and Cold Knife Conization. ( 25089550 )
2014
30
Genomic alterations in pulmonary adenocarcinoma in situ in an adolescent patient. ( 24678688 )
2014
31
Pathogenesis of combined high-grade squamous intraepithelial lesion and adenocarcinoma in situ of the uterine cervix: human papillomavirus genotype and methylation status and immunohistochemical study. ( 25612672 )
2014
32
A report of adenocarcinoma in situ and congenital pulmonary airway malformation in a three-day-old infant with a review of the literature. ( 25341604 )
2014
33
Clinical outcomes of patients with adenocarcinoma in situ of the cervix treated by conization. ( 25556268 )
2014
34
Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix. ( 25284039 )
2014
35
Adenocarcinoma in situ of the uterine cervix-a systematic review. ( 25238167 )
2014
36
Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. ( 24811831 )
2014
37
A Case of HPV-negative Intestinal-type Endocervical Adenocarcinoma In Situ With Coexisting Multifocal Intestinal and Gastric Metaplasia. ( 24418863 )
2014
38
Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section CT scan. ( 24351509 )
2013
39
Long-term follow-up results from women with cervical adenocarcinoma in situ treated by conization: an experience from a large academic women's hospital. ( 23903202 )
2013
40
Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ. ( 23946807 )
2013
41
Conization using the Shimodaira-Taniguchi procedure for adenocarcinoma in situ of the uterine cervix. ( 23395556 )
2013
42
Potential effects of updated pap test screening guidelines and adenocarcinoma in situ of the cervix. ( 23635675 )
2013
43
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. ( 23541795 )
2013
44
Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. ( 23591077 )
2013
45
PAX8 and PAX2 expression in endocervical adenocarcinoma in situ and high-grade squamous dysplasia. ( 23202787 )
2013
46
Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. ( 23552379 )
2013
47
The value of CT attenuation in distinguishing atypical adenomatous hyperplasia from adenocarcinoma in situ. ( 24229623 )
2013
48
Conization using the Shimodaira-Taniguchi procedure for adenocarcinoma in situ of the uterine cervix. ( 23790263 )
2013
49
A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung. ( 23617234 )
2013
50
Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. ( 24370689 )
2013

Variations for Adenocarcinoma in Situ

Expression for Adenocarcinoma in Situ

Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Pathways for Adenocarcinoma in Situ

GO Terms for Adenocarcinoma in Situ

Cellular components related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.26 CDKN1A CDX2 PAX2 TOP2A
2 nucleolus GO:0005730 9.1 CDKN1A CDKN2A MCM2 PAX2 TOP2A WT1

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.97 CDKN2A CDX2 PAX2 PAX8 WT1
2 negative regulation of cell growth GO:0030308 9.8 CDKN1A CDKN2A WT1
3 G1/S transition of mitotic cell cycle GO:0000082 9.78 CDKN1A CDKN2A MCM2
4 Ras protein signal transduction GO:0007265 9.73 CDKN1A CDKN2A KRAS
5 cochlea development GO:0090102 9.65 MCM2 PAX2
6 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.65 CDKN1A CDKN2A
7 cellular senescence GO:0090398 9.64 CDKN1A CDKN2A
8 negative regulation of phosphorylation GO:0042326 9.64 CDKN1A CDKN2A
9 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.63 PAX2 PAX8
10 urogenital system development GO:0001655 9.63 PAX2 PAX8
11 mesonephros development GO:0001823 9.62 PAX2 PAX8
12 replicative senescence GO:0090399 9.61 CDKN1A CDKN2A
13 branching involved in ureteric bud morphogenesis GO:0001658 9.61 PAX2 PAX8 WT1
14 mesenchymal to epithelial transition GO:0060231 9.6 PAX2 WT1
15 positive regulation of cellular senescence GO:2000774 9.59 CDKN2A KRAS
16 cellular response to gonadotropin stimulus GO:0071371 9.58 PAX8 WT1
17 metanephric mesenchyme development GO:0072075 9.58 PAX2 WT1
18 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.55 PAX2 PAX8
19 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.54 PAX2 PAX8
20 pronephros development GO:0048793 9.52 PAX2 PAX8
21 metanephric S-shaped body morphogenesis GO:0072284 9.51 PAX8 WT1
22 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.49 PAX2 PAX8
23 metanephric nephron tubule formation GO:0072289 9.48 PAX2 PAX8
24 metanephric distal convoluted tubule development GO:0072221 9.46 PAX2 PAX8
25 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.4 PAX2 PAX8
26 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.37 PAX2 PAX8
27 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.32 PAX2 PAX8
28 positive regulation of metanephric DCT cell differentiation GO:2000594 9.26 PAX2 PAX8
29 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.16 PAX2 PAX8
30 pronephric field specification GO:0039003 8.96 PAX2 PAX8
31 metanephric epithelium development GO:0072207 8.8 PAX2 PAX8 WT1
32 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.05 CDKN2A PAX2 PAX8 TOP2A WT1

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.5 CDKN2A CDX2 MCM2 PAX2 PAX8 TOP2A
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN1A CDKN2A

Sources for Adenocarcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....